IgA nephropathy

E Stamellou, C Seikrit, SCW Tang, P Boor… - Nature Reviews …, 2023 - nature.com
IgA nephropathy (IgAN), the most prevalent primary glomerulonephritis worldwide, carries a
considerable lifetime risk of kidney failure. Clinical manifestations of IgAN vary from …

IgA nephropathy: an interesting autoimmune kidney disease

A Rajasekaran, BA Julian, DV Rizk - The American journal of the medical …, 2021 - Elsevier
Immunoglobulin A nephropathy (IgAN) is the most common primary glomerulonephritis
worldwide. It is a leading cause of chronic kidney disease and progresses to end-stage …

IgA nephropathy

JC Rodrigues, M Haas, HN Reich - Clinical Journal of the …, 2017 - journals.lww.com
IgA nephropathy (IgAN) is a leading cause of CKD and renal failure. Recent international
collaborative efforts have led to important discoveries that have improved our understanding …

Therapeutic targeting of the complement system: from rare diseases to pandemics

P Garred, AJ Tenner, TE Mollnes - Pharmacological reviews, 2021 - ASPET
The complement system was discovered at the end of the 19th century as a heat-labile
plasma component that “complemented” the antibodies in killing microbes, hence the name …

IgA vasculitis update: epidemiology, pathogenesis, and biomarkers

L Xu, Y Li, X Wu - Frontiers in Immunology, 2022 - frontiersin.org
Immunoglobulin A vasculitis (IgAV), formerly known as Henoch-Schönlein purpura, is the
most common systemic vasculitis in children, characterized by diverse clinical …

[HTML][HTML] New insights in the pathogenesis of immunoglobulin A vasculitis (Henoch-Schönlein purpura)

MH Heineke, AV Ballering, A Jamin, SB Mkaddem… - Autoimmunity …, 2017 - Elsevier
Immunoglobulin A vasculitis (IgAV), also referred to as Henoch-Schönlein purpura, is the
most common form of childhood vasculitis. The pathogenesis of IgAV is still largely …

IgA nephropathy

RJ Wyatt, BA Julian - New England Journal of Medicine, 2013 - Mass Medical Soc
IgA nephropathy is a common glomerular disease that is an important cause of kidney
failure. This review discusses advances in the therapy and understanding of the molecular …

[HTML][HTML] Safety, tolerability and efficacy of narsoplimab, a novel MASP-2 inhibitor for the treatment of IgA nephropathy

RA Lafayette, BH Rovin, HN Reich, JA Tumlin… - Kidney international …, 2020 - Elsevier
Introduction Narsoplimab is a human monoclonal antibody against mannan-associated
lectin-binding serine protease− 2 (MASP-2). Now in a phase 3 study, narsoplimab was …

Current understanding of the role of complement in IgA nephropathy

N Maillard, RJ Wyatt, BA Julian, K Kiryluk… - Journal of the …, 2015 - journals.lww.com
Complement activation has a role in the pathogenesis of IgA nephropathy, an autoimmune
disease mediated by pathogenic immune complexes consisting of galactose-deficient IgA1 …

[HTML][HTML] New developments in the genetics, pathogenesis, and therapy of IgA nephropathy

R Magistroni, VD D'Agati, GB Appel, K Kiryluk - Kidney international, 2015 - Elsevier
Recent years have brought notable progress in the field of IgA nephropathy. Here, we
highlight important new directions and latest developments, including successful discovery …